Acurx Pharmaceuticals, Inc Reports First Quarter 2024 Results and Provides Business Update prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of.
/PRNewswire/ Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of.
Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results from the ibezapolstat Phase 2 clinical.
STATEN ISLAND, N.Y., April 23, 2024 /PRNewswire/ Acurx Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial.